# A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.

> **NCT05668091** · PHASE2 · COMPLETED · sponsor: **Harlan M Krumholz** · enrollment: 100 (actual)

## Conditions studied

- Long COVID

## Interventions

- **DRUG:** Nirmatrelvir
- **DRUG:** Ritonavir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05668091
- **Lead sponsor:** Harlan M Krumholz
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-14
- **Primary completion:** 2024-04-09
- **Final completion:** 2024-08-21
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05668091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05668091, "A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05668091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*